Below are the most recent publications written about "Hemophilia A" by people in Profiles.
-
Joo JH, Wang X, Singh S, Chen CY, Li C, Adair JE, Kiem HP, Rawlings DJ, Miao CH. Intraosseous delivery of platelet-targeted factor VIII lentiviral vector in humanized NBSGW mice. Blood Adv. 2022 10 11; 6(19):5556-5569.
-
Latef TJ, Bhardwaj P, Bilal M. Refractory acquired haemophilia A in a patient with HIV treated with Emicizumab. Blood Coagul Fibrinolysis. 2022 Mar 01; 33(2):138-140.
-
Croteau SE, Frelinger AL, Gerrits AJ, Michelson AD. Decreased platelet surface phosphatidylserine predicts increased bleeding in patients with severe factor VIII deficiency. J Thromb Haemost. 2021 04; 19(4):976-982.
-
Gundabolu K, Goldsweig A, Bhatt VR, Koepsell SA, Harper JL. ST-Segment Elevation Myocardial Infarction (STEMI) and Pulmonary Embolism in a Hemophilia A Patient Receiving Emicizumab and recombinant Activated Factor VII. Haemophilia. 2020 Jan; 26(1):e5-e8.
-
Chang IJ, Byers HM, Ng BG, Merritt JL, Gilmore R, Shrimal S, Wei W, Zhang Y, Blair AB, Freeze HH, Zhang B, Lam C. Factor VIII and vWF deficiency in STT3A-CDG. J Inherit Metab Dis. 2019 03; 42(2):325-332.
-
Boylan B, Rice AS, Dunn AL, Tarantino MD, Brettler DB, Barrett JC, Miller CH. Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay. J Thromb Haemost. 2015 Jan; 13(1):47-53.
-
Muzaffar J, Katragadda L, Haider S, Javed A, Anaissie E, Usmani S. Rituximab and intravenous immunoglobulin (IVIG) for the management of acquired factor VIII inhibitor in multiple myeloma: case report and review of literature. Int J Hematol. 2012 Jan; 95(1):102-6.
-
Brettler DB. Gene therapy for hemophilia? J Thromb Haemost. 2005 Jun; 3(6):1317-9.
-
Qin H, Shire NJ, Keenan ED, Rouster SD, Eyster ME, Goedert JJ, Koziel MJ, Sherman KE. HCV quasispecies evolution: association with progression to end-stage liver disease in hemophiliacs infected with HCV or HCV/HIV. Blood. 2005 Jan 15; 105(2):533-41.
-
Xu L, Daly T, Gao C, Flotte TR, Song S, Byrne BJ, Sands MS, Parker Ponder K. CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. Hum Gene Ther. 2001 Mar 20; 12(5):563-73.